New data demonstrating the strength of Novartis' hematology portfolio to be presented

[News]

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

More... (http://www.news-medical.net/news/20091202/New-data-demonstrating-the-strength-of-Novartis-hematology-portfolio-to-be-presented.aspx)